Program
vortosiran
Its studies are mostly in Atrial Fibrillation · Venous Thromboembolism, led by Suzhou Ribo Life Science.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Suzhou Ribo Life Science | 22 open or running | phase 2since Sep 17, 2026 | Sep 17, 2026 | Jul 2027phase 2 · NCT07850453 |
Also a collaborator on its studies: Link Medical Research AB and Fortrea.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Feb 13, 2025Named vortosiranINNProposed as its International Nonproprietary Name in WHO's List 132
- Sep 17, 2026First studies: 2 phase 2 studiesFirst studyNCT07850453, NCT07870889
Ahead
- Jul 2027Primary completion: phase 2 study in Venous ThromboembolismNCT07850453
- Jul 31, 2028Primary completion: phase 2 study in Atrial FibrillationNCT07870889
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07870889Atrial Fibrillation · Denmark, Norway, Poland and more | 2 | Not yet recruiting | Jul 31, 2028 | 150 |
| NCT07850453Venous Thromboembolism · Bulgaria, France, Poland and more | 2 | Not yet recruiting | Jul 2027 | 150 |
How it is read
Names in the registry
- “Vortosiran”, 3 entries
Conditions, from the studies’ own filings
- Atrial Fibrillation, 1 study
- Venous Thromboembolism, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.